CEO COMMENTS

My first weeks as CEO of SpectraCure have gone by fast, and they were fast-paced and very interesting. I have had meetings with all employees to acquaint myself with the technology, the clinical trial and the collaborations that are underway, and I have also held discussions with the Board of Directors. I am impressed by the determination and commitment I see around me, and I am getting a clearer picture of the company, our current situation and our focus in the short and long term.

I note that the technology developed by SpectraCure offers a wide range of possibilities for the treatment of cancer with PDT. The strategy and focus on treatment of recurrent prostate cancer, where alternatives are scarce, non-curative and associated with undesirable side effects, appear to be pertinent. At the same time, positive results in this area will pave the way for additional interesting indications, obviously including the treatment of primary prostate cancer. The further-developed laser device, which will be more convenient to use in the continued clinical trial, in combination with the IDOSE® dose planning platform, provide for effective and personalized treatment. The cooperation that SpectraCure has engaged in with the Royal Free London NHS Foundation Trust, relating to breast cancer treatment with PDT to assess the possibility of using PDT as a first alternative to surgery and radiotherapy, is an interesting example of the interest in the application of SpectraCure’s therapy in other indications.

I feel a powerful support from the company’s Board of Directors and, at the same time, welcome that the Nomination Committee has proposed Dr. Homer Pien as a new addition to the Board. I have had the privilege of getting to know Homer during my tenure at Philips, and I look forward to the opportunity to benefit from the breadh and depth of his skills, which range from development and innovation to strategic positioning and commercialization.

In the light of the foregoing, I look forward with confidence to the patient treatments in our clinical study being able to restart as soon as possible, while I vigorously start working on the commercial strategic issues. Together with SpectraCure’s competent staff and dedicated Board, we will reach the goal – to introduce and commercialize SpectraCure’s treatment system.

During the quarter and the process that preceded my decision to accept the role as CEO of the company, I made note of certain press coverage that partly involved SpectraCure. I am of the firm opinion that this publicity in no way is relevant to the actual position of SpectraCure today, or its future potential.

Finally, I would like to thank Masoud Khayyami and my colleagues for an introduction well implemented. I eagerly look forward to the continued work, alongside the staff as well as the Board of Directors.

 

Lund, May 2021

Johan Folkunger
CEO of SpectraCure AB (publ)